CRYO CELL INTERNATIONAL INC financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data CRYO CELL INTERNATIONAL INC files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	23.1	25.4	29.2	31.8	31.1	28.9	30.3	31.3	32	31.6
Cost of revenue	5.77	6.72	8.54	10	9.66	8.99	8.79	8.39	7.95	7.38
Gross profit	17.4	18.7	20.7	21.8	21.5	19.9	21.5	23	24	24.2
Research and development	0.05	0.04	0.09	0.03	0.02	0.05	0.38	1.17	1.24	0.38
Selling, general and administrative	14.7	13.5	15.6	14.9	14.3	14.6	15.6	17.2	18.5	18.2
Operating income	0.43	5.01	5.19	5.06	7.66	4.02	4.02	-12.3	3.48	0.48
Interest expense	0.95	1.3	1.55	1.7	1.54	1.38	1.52	1.24	1.86	2.07
Other non-operating income	-2.91	-1.38	-1.57	-1.67	-2.62	-1.41	-0.71	-1.06	-0.68	-2.82
Pre-tax income	-2.48	3.62	3.62	3.39	5.04	2.61	3.32	-13.4	2.8	-2.34
Income tax	-1.16	1.31	4.47	1.1	1.41	0.53	0.55	-3.84	2.4	0.09
Net income	-1.32	2.32	-0.85	2.29	3.62	2.08	2.77	-9.52	0.4	-2.43
EBITDA	0.59	5.14	5.51	5.46	8.03	5.06	5.52	-10.9	4.17	1.47
EPS, basic	-0.16	0.33	-0.11	0.29	0.48	0.26	0.33	-1.14	0.05	-0.30
EPS, diluted	-0.16	0.30	-0.11	0.27	0.45	0.25	0.33	-1.14	0.05	-0.30
Shares, basic (weighted)	8.11	7.06	7.46	7.79	7.54	8.14	8.47	8.34	8.13	8.07
Shares, diluted (weighted)	8.11	7.65	7.46	8.41	8.14	8.36	8.48	8.34	8.21	8.07
Dividend per share							0.90		0.25

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	3.5	6.28	6.04	6.54	10.4	8.26	1.7	0.41	0.56	0.32
Short-term investments	0.62	0.44	0.88	0.9	0.09	0.08	0.02	0.57	2.94	2.98
Receivables	4.05	5.13	5.87	6.1	6.32	5.25	6.04	6.58	7.31	6.85
Inventory	0.36	0.31	1.26	1.08	0.93	0.92	0.85	0.77	0.66	0.41
Other current assets	0.08	0.21	0.25	0.26	0.24	0.71	0.43	0.39	0.45	0.63
Total current assets	9.01	12.7	14.8	15.4	18.6	15.8	9.61	9.45	12.6	11.8
Property, plant and equipment	0.98	0.88	1.49	1.85	1.64	3.23	13.6	21	21.9	21
Lease right-of-use assets					0.3	0.53	0.61	1.03	0.81	0.82
Goodwill	0	0	1.94	1.94	1.94	1.94	1.94	1.94	1.94	1.94
Intangible assets	0.26	0.23	1.34	1.25	1.18	1.56	1.46	0.99	0.92	0.86
Other non-current assets	9.55	10.3	26.1	25.7	26	41.6	41.7	30.8	30.2	28.9
Total assets	19.5	23.9	42.9	42.9	46.2	60.7	64.9	64.7	64.7	61.7
Accounts payable	1.49	1.93	1.26	1.37	0.96	1.49	1.61	3.17	1.88	2.87
Accrued liabilities	2.55	2.58	2.7	2.09	2.9	3.06	3.59	5.17	5.81	4.28
Deferred revenue	7.07	7.43	8.37	8.88	9.18	9.36	9.59	9.7	9.79	9.73
Total current liabilities	13.1	13.9	15.4	15.4	16.4	21.1	19.5	20.9	21.6	19.8
Long-term debt	1.43	1.43	1.43	5.86	2.84	0	8.58	8.43	8.31	8.17
Lease liabilities					0.02	0.24	0.31	0.85	0.51	0.47
Other non-current liabilities	21.8	22.5	35.9	34.4	32.5	35.4	46.9	51.4	56.3	60.5
Total liabilities	35	36.4	51.3	49.8	48.9	56.5	66.4	72.3	77.9	80.3
Total debt	9.82	7.3	12.9	8.96	5.94	1.9	8.73	8.6	8.48	8.35
Paid-in capital	30.3	31.4	35.5	35.9	36.6	41.6	42.6	43.4	44.3	44.7
Retained earnings	-26.8	-24.5	-25.3	-22.4	-18.8	-16.7	-21.6	-31.2	-32.8	-38.4
Treasury stock	-19.1	-19.6	-19.6	-20.6	-20.6	-20.8	-22.6	-23.4	-24.9	-25
Other comprehensive income	0.03	0.04	0.34
Shareholders' equity	-15.4	-12.5	-8.91	-6.95	-2.67	4.18	-1.52	-11	-13.2	-18.6
Total equity	-15.4	-12.5	-8.91	-6.95	-2.67	4.18	-1.52	-11	-13.2	-18.6
Total liabilities and equity	19.5	23.9	42.4	42.9	46.2	60.7	64.9	61.2	64.7	61.7
Shares outstanding	6.79	7.1	7.8	7.51	7.55	8.55	8.5	8.29	8.08	8.06

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-1.32	2.32	-0.85	2.29	3.62	2.08	2.77	-9.52	0.4	-2.43
Depreciation and amortization	0.15	0.13	0.32	0.4	0.37	1.04	1.5	1.4	0.69	0.99
Stock-based compensation	1.77	0.97	0.48	0.4	0.62	0.3	0.46	0.82	0.78	0.42
Deferred income tax	-1.91	-0.77	2.28	-1.41	-1.01	-1.65	-1.73	-6.75	-0.31	-2.82
Change in receivables	-1.62	-1.15	-1.35	-1	-0.83	0.53	-1.72	-1.57	-2	-0.41
Change in inventory	0.11	0.05	0.32	-0.03	0.45	0.21	0.49	0.36	0.43	0.06
Change in payables	0.33	0.44	-0.67	0.11	-0.41	0.53	0.12	0.69	-0.42	1
Cash from operations	4.99	5.72	5.33	6.29	8.47	7.93	8.57	8.92	6.01	5.48
Capital expenditures	-0.34	-0.1	-0.45	-0.66	-0.1	-1.83	-12.2	-6.84	-2.4	-0.23
Acquisitions			-10.5
Purchases of investments					-0.35
Sales and maturities of investments					0.81	0	1.16	0.4	1.52	2.79
Cash from investing	-0.37	0.09	-11.3	-0.66	0.36	-6.95	-15.3	-8.14	-4.88	-0.98
Stock issued	0.04	0.06	0.17	0.01	0.04	1.28	0.55	0	0.08	0.02
Share buybacks	-10.8	-0.45		-0.99		-0.25	-1.82	-0.8	-1.42	-0.17
Dividends paid						0	-7.67	0	-2.02	-3.23
Cash from financing	-5.27	-3.03	5.71	-5.13	-5	-3.07	0.15	-2.07	-0.98	-4.75
Net change in cash	-0.65	2.78	-0.24	0.5	3.82	-2.1	-6.56	-1.3	0.15	-0.24
Free cash flow	4.64	5.62	4.89	5.63	8.37	6.09	-3.6	2.08	3.61	5.25
Interest paid						1.04	1.26	1.81	1.98	2.03
Income taxes paid						3.53	1.57	1.82	2.72	4.59

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to May 31, 2026; growth uses fiscal years. Valuation uses the share price of $4.24 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	77.9%	Gross profit / revenue.
Operating margin	-0.3%	Operating income / revenue.
EBITDA margin	2.4%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	-8.2%	Pre-tax income / revenue.
Net margin	-7.9%	Net income / revenue.
FCF margin	19.6%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	20.3%	Cash from operations / revenue.
Return on assets (ROA)	-4.1%	Net income / average total assets.
R&D / revenue	1.0%	Research and development expense / revenue.
SG&A / revenue	60.9%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	1.0%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	0.7%	Capital expenditures / revenue.
D&A / revenue	2.8%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	-1.3%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	1.3%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	0.3%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	0.6%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	3.9%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	2.4%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	-86.1%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 3y	-50.7%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 5y	-42.5%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	-64.8%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	-35.7%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	-28.8%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	-704.2%	Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y	-700.0%	EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y	-8.9%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	-13.9%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	-8.3%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	45.5%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 5y	-8.9%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-4.6%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-1.7%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	6.0%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-1.8%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-1.7%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	-0.2%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	0.71x	Current assets / current liabilities.
Quick ratio	0.63x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.20x	(Cash + short-term investments) / current liabilities.
Debt / assets	13.6%	Total debt / total assets.
Liabilities / assets	129.3%	Total liabilities / total assets.
Net debt	$5.1M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	6.79x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage	-0.05x	Operating income / interest expense.
Working capital	-$4.6M	Current assets - current liabilities.
Goodwill and intangibles / assets	4.6%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$20.5M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.51x	Revenue / average total assets.
Fixed asset turnover	1.51x	Revenue / average property, plant and equipment.
Inventory turnover	22.1x	Cost of revenue / average inventory.
Days inventory	16 days	365 x average inventory / cost of revenue.
Receivables turnover	4.50x	Revenue / average receivables.
Days sales outstanding	81 days	365 x average receivables / revenue.
Days payables	151 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	-54 days	Days inventory + days sales outstanding - days payables.
Capex / operating cash flow	3.3%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$0.31	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$3.86	Revenue / diluted weighted shares.
FCF per share	$0.76	Free cash flow / diluted weighted shares.
Operating cash flow per share	$0.78	Cash from operations / diluted weighted shares.
Book value per share	-$2.20	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$2.55	Tangible book value / shares outstanding.
Cash per share	$0.39	(Cash + short-term investments) / shares outstanding.
Dividends / FCF	0.0%	Dividends paid / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$34.2M	Share price x shares outstanding.
Enterprise value	$39.3M	Market cap + total debt - cash - short-term investments.
P/S	1.10x	Market cap / revenue.
P/FCF	5.60x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	5.41x	Market cap / cash from operations, when positive.
EV/Sales	1.26x	Enterprise value / revenue.
EV/EBITDA	52.2x	Enterprise value / EBITDA, when both are positive.
EV/FCF	6.43x	Enterprise value / free cash flow, when both are positive.
FCF yield	17.9%	Free cash flow / market cap.
Earnings yield	-7.2%	Net income / market cap (the inverse of P/E).
Dividend yield	0.0%	Dividends paid over the period / market cap.
Shareholder yield	0.0%	(Dividends paid + share buybacks) / market cap.

What was CRYO CELL INTERNATIONAL INC's revenue in fiscal 2025?

CRYO CELL INTERNATIONAL INC reported revenue of $31.6M for fiscal 2025, 1.3% lower than the year before.

Was CRYO CELL INTERNATIONAL INC profitable in fiscal 2025?

No. It reported a net loss of $2.4M.

How much free cash flow did CRYO CELL INTERNATIONAL INC generate in fiscal 2025?

Cash from operations of $5.5M minus capital expenditures of $230.5K left free cash flow of $5.2M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to CRYO CELL INTERNATIONAL INC